ModifiedUnitedHealthcarePolicy CS086KS.02

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kansas Only)

Clinical coverage rules and evidence summary for occipital nerve injections and ablation (including occipital neuralgia and headache) applicable to UnitedHealthcare members in Kansas aged adults and children where specified.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kansas Only)

Policy CodePolicy CS086KS.02

Change TypeMaterial coverage updatedefinitions added

Effective DateOct 1, 2025

Next Review Date

Key ActionDocument prior conservative therapy failure and diagnostic block response when requesting authorization; note occipital nerve ablation is proven for malignancy-related head/neck pain.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck.

Removed instruction to refer to the InterQual® CP: Procedures, Neuroablation, Percutaneous for medical necessity clinical coverage criteria for occipital nerve ablation for severe cancer pain due to malignancy involving the head and neck.

Added definitions for the Migraine Disability Assessment Test (MIDAS) and Migraine-Specific Quality of Life Questionnaire (MSQ).

Kansas-onlystate-specific policy

1material coverage change

2new definitions

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

procedures listed as unproven

≥50%typical trial threshold

Coverage criteria and evidence summary

Coverage statements by population and indication

Coverage stance summarized by population and indication

Adults - malignancy-related head/neck pain: Injection of local anesthetics and/or steroids used as greater occipital nerve blocks is proven and medically necessary for treating pain due to malignancy involving the head and neck; for occipital nerve ablation for severe cancer pain in adults, InterQual neuroablation procedures were previously referenced.

Applies to members 18 years and older; see InterQual as previously referenced for ablation criteria

Adults - occipital neuralgia / headache: The following are considered unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches (including migraine and cervicogenic headache) due to insufficient evidence: injection of local anesthetics and/or steroids used as GONBs for routine chronic preventive use, neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1-C3 rhizotomy, radiofrequency ablation (thermal or pulsed) or denervation, rhizotomy of C1-C3 spinal dorsal roots, surgical decompression of second cervical nerve root and ganglion, and surgical decompression of the greater occipital nerve.

Applies to members 18 years and older; listed procedures lack sufficient evidence

Pediatrics - malignancy-related head/neck pain: Injection of local anesthetics and/or steroids used as greater occipital nerve blocks and occipital nerve ablation (destruction by neurolytic agent) are proven and medically necessary for treating pain due to malignancy involving the head and neck in members under 18.

Pediatric malignancy exception per policy revision

Pediatrics - occipital neuralgia / headache: The following are unproven and not medically necessary for diagnosing and/or treating occipital neuralgia or headaches in members under 18 due to insufficient evidence: injection of local anesthetics/steroids used as GONBs for routine chronic preventive use, neurostimulation/electrical stimulation, occipital neurectomy, partial posterior intradural C1-C3 rhizotomy, radiofrequency ablation or denervation, rhizotomy of C1-C3 spinal dorsal roots, surgical decompression of second cervical nerve root and ganglion, and surgical decompression of the greater occipital nerve.

Pediatric non-malignancy treatments considered unproven

Coverage-relevant evidence summaries

Evidence-based coverage considerations (summary of findings)

GONB short-term benefits: Systematic reviews and randomized trials show GONB with local anesthetic can reduce headache intensity and frequency in the short term (approximately 1–2 months), but the overall quality of evidence is limited and imprecision/risk of bias is common.

Meta-analyses (e.g., Velásquez-Rimachi) and HTA (Hayes) report short-term reductions in intensity and headache days

Role of corticosteroids: Adding corticosteroids to local anesthetic for GONB has not consistently demonstrated additional benefit in most analyses.

Velásquez-Rimachi and other reviews found no clear additive benefit

Limited evidence for chronic preventive use: Evidence for chronic or repeated GONB as a long-term preventive therapy is limited and low quality; benefits beyond short-term follow-up are uncertain and larger, well-designed trials are needed.

Hayes HTA concluded little to no evidence supporting chronic use

Coverage criteria for surgical or RFA interventions

Covered when ALL of the following are met

Primary criteria: 1) Documented diagnosis of occipital neuralgia, cervicogenic headache, or a defined refractory headache disorder; 2) Documentation of failure of appropriate conservative therapies (e.g., medications, physical therapy); 3) Positive diagnostic nerve block response or other documented predictor of success (for example, ≥50% temporary pain relief after a diagnostic GONB or C2 DRG block); 4) Procedure performed by or in consultation with an appropriate specialist (pain physician, neurologist, neurosurgeon, or equivalent).

Evidence and guidelines identify prior positive block response and specialist involvement as predictors/requirements for proceeding to RFA or surgery

Not medically necessary / Experimental

Not covered or considered experimental when ANY of the following apply

Exclusion criteria: 1) Occipital neurectomy or nerve decompression for headaches when evidence is insufficient to establish long-term efficacy; 2) Decompression procedures for auriculotemporal, supratrochlear/supraorbital nerve (SON) or other cranial nerve decompressions lacking RCT evidence; 3) Nonpulsed (thermal) percutaneous radiofrequency ablation for occipital neuralgia when adequate supportive evidence is lacking.

Multiple evidence reviews identify insufficient RCT-level data and low-quality evidence for these procedures

Selection and evidence considerations

Evidence-based considerations and common selection practices reported in the literature

Selection and evidence considerations for neurostimulation/PRF: Select patients with medically refractory headache disorders after documented failure of conservative therapies; many studies require a positive temporary trial of stimulation (commonly ≥50% improvement) before permanent implantation; reported long-term benefit is variable and evidence quality is low; device complication risks must be weighed in selection.≥ 50% temporary improvement commonly used

Hayes HTA and systematic reviews describe trial-based selection and variable responder rates

Potential appropriate use for invasive ONS

Summary of evidence-based coverage considerations

Invasive ONS potentially appropriate when: All of the following: (1) Medically refractory chronic headache disorder (e.g., chronic migraine or occipital neuralgia) with documented failure of conventional medical therapies; (2) Positive short-term trial of occipital nerve stimulation with a commonly used threshold of ≥50% pain reduction during the trial; (3) Evaluation and management at a tertiary or specialist center with multidisciplinary assessment; (4) Informed consent acknowledging device-related risks and potential for additional surgeries.

Derived from Hayes assessments, consensus guidance, and device literature recommending trial-based selection and specialist involvement

Noninvasive device consideration

Noninvasive neuromodulation coverage considerations

Noninvasive neuromodulation may be considered when: One or more of the following: (a) Patient has chronic or episodic migraine with inadequate response or intolerance to medication therapies; (b) Patient prefers a nondrug therapy; (c) Specific device-level evidence supports use for the indication (for example REN for acute treatment or device-specific RCT data for certain TENS/PENS/eTNS applications), acknowledging that overall evidence quality is often low to very low.

Systematic reviews and trials report some positive effects for REN, TENS/PENS, eTNS but emphasize low-quality evidence and need for further research

Guideline-based recommendations

Guideline-based coverage considerations and recommended use-conditions

Guideline stances: Guidelines (e.g., VA/DoD, NICE) generally find evidence insufficient to recommend many neuromodulation techniques for routine use; NICE allows transcutaneous SON stimulation for acute migraine only with special arrangements for governance, consent, and audit, and recommends preventive use only in research contexts.

Recommendations emphasize prior use of established medical therapies and specialist selection

Device regulation and evidence influence

Device and regulatory context relevant to coverage decisions

Device considerations: Devices used for RFA and electrical stimulation are regulated via FDA pathways (510(k) or De Novo) with product codes for RFA generators/probes and electrical stimulation devices; device clearance is informational and does not by itself determine coverage, while the variable strength of clinical evidence should inform coverage judgments.

FDA product codes GXD/GXI for RFA and GZF/GZB/PCC (and specific clearances such as K203181 for Nerivio) are noted in device context

Neurolytic ablation for malignancy — covered

Policy modification for occipital nerve ablation in malignant pain

Neurolytic ablation for malignancy: Occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck.

This language was added in the policy revision and applies across specified age groups as noted

The policy references a range of procedures used to diagnose or manage occipital neuralgia and related headaches. These include diagnostic and therapeutic greater occipital nerve blocks (GONB) (local anesthetic, with or without corticosteroid), image‑guided peripheral nerve injections, and short series injections reported in trials for short‑term relief. Surgical and invasive interventions discussed across the evidence base include occipital neurectomy, various nerve decompression and neuroplasty techniques, and ablative procedures such as radiofrequency ablation (thermal and pulsed) or denervation. Implantable options and electrical therapies are also described, including peripheral/occipital neurostimulation systems and noninvasive neuromodulation devices (e.g., eTNS/SON devices).

Evidence summaries cited in the policy indicate that GONB can provide short‑term reductions in headache intensity or frequency but that the literature is heterogeneous and limited for chronic preventive use, while surgical and ablation approaches lack consistent, high‑quality RCT evidence establishing long‑term effectiveness.

The policy states that neuroplasty for occipital neuralgia lacks sufficient high‑quality evidence to establish safety and effectiveness. A 2024 Hayes brief summarized available publications but identified no randomized controlled trials and concluded that the current literature is inadequate to draw definitive conclusions about neuroplasty for occipital neuralgia.

Because of the absence of RCTs and limited peer‑reviewed data, neuroplasty is listed among procedures considered unproven and not medically necessary for diagnosing or treating occipital neuralgia or related headaches.

The policy identifies occipital neurectomy and surgical nerve decompression as interventions for which the available evidence is insufficient to conclude long‑term effectiveness; published studies and systematic reviews do not establish durable benefit in well‑designed clinical trials.

Similarly, nonpulsed (thermal) percutaneous radiofrequency ablation (RFA) is described in evidence reviews as having limited or no RCT data at the time of the review, and the body of peer‑reviewed literature was judged inadequate for full assessment. These procedures are therefore considered unproven or not medically necessary for occipital neuralgia/headache indications outside of clearly documented, exceptional contexts.

The policy summarizes that evidence for neurostimulation (implantable occipital nerve stimulation and other peripheral nerve stimulation) is limited and methodologically heterogeneous. Systematic reviews report variable response rates across disorders and studies, and many series are retrospective or lack adequate control groups.

Because of these limitations — including small sample sizes, inconsistent outcomes, and device‑related complications reported across studies — neurostimulation is described as having insufficient high‑quality evidence to support broad routine coverage for many headache indications without clear documentation of prior conservative therapy failure and, when applicable, a positive temporary trial response.

Occipital nerve stimulation (ONS) is specifically highlighted as having very low or inconsistent evidence for some indications, most notably chronic cluster headache. Hayes and other assessments found small case series and poor‑quality comparative data, with reported responder rates varying widely and meaningful complication rates (e.g., infection, lead migration) described.

Given the limited, low‑quality evidence and the frequency of device‑related adverse events, the policy indicates concerns about using ONS for chronic cluster headache and other off‑label headache indications outside research or carefully selected tertiary‑center contexts.

The policy notes that botulinum toxin A (BTX‑A) is not FDA‑approved specifically for cervicogenic headache or occipital neuralgia and therefore its use for these diagnoses is considered off‑label. The absence of an approval for these specific indications is cited as a rationale for treating BTX‑A use in cervicogenic headache/occipital neuralgia as outside established labeled indications.

The policy was revised to remove the prior instruction to refer to InterQual® CP: Procedures, Neuroablation, Percutaneous when considering occipital nerve ablation for severe cancer‑related head and neck pain. That referral instruction was explicitly removed in the October 1, 2025 policy update.

The document also adds direct coverage language for neurolytic occipital nerve ablation in malignant pain, eliminating the prior requirement to consult InterQual® for that specific cancer‑pain indication.

Across the policy, a consistent list of interventional approaches is referenced: injectable occipital nerve blocks (GONB/LON), image‑guided nerve injections, neurolytic occipital nerve ablation, radiofrequency ablation (pulsed and thermal), percutaneous and open neurectomy/decompression and neuroplasty techniques, and neurostimulation strategies including peripheral/occipital leads and noninvasive neuromodulation devices.

These interventions are discussed in the context of their variable evidence bases, procedural considerations (image guidance, specialist involvement), and differing coverage positions depending on indication (e.g., malignancy versus non‑malignant occipital neuralgia/headache).

The policy states that repeated use of GONB as a long‑term preventive strategy lacks sufficient supportive evidence and therefore may be considered not medically necessary when used chronically without documented short‑term effectiveness and justification.

Evidence reviews (e.g., Hayes) emphasize that benefits from GONB are typically short‑term and that trials frequently evaluated single injections or short series, leaving uncertainty about ongoing preventive benefit.

The policy reiterates that procedures with inadequate evidence include occipital neurectomy, nerve decompression techniques, neuroplasty, and nonpulsed (thermal) RFA for occipital neuralgia or headaches. These interventions are repeatedly characterized in evidence summaries as lacking RCT evidence or robust long‑term data and therefore may be classified as not medically necessary or experimental for non‑malignant indications.

Providers requesting authorization for these procedures should include comprehensive documentation because the policy identifies an increased risk of denial where supportive evidence is not present.

The policy states that routine use of implantable neurostimulation or pulsed radiofrequency is not supported without documented failure of conservative measures and, for permanent implants, a positive temporary trial response. Many studies and reviews selected patients after multiple medical therapy failures, and guideline summaries recommend a conservative‑first approach.

For selection of permanent ONS, the literature commonly uses a temporary trial threshold of ≥ 50% pain reduction to identify responders prior to implantation.

The policy emphasizes that evidence for ONS in many indications (for example, chronic cluster headache and several off‑label headache types) is very low or inconsistent. Hayes and guideline panels found small case series, heterogeneous outcomes, and complication rates that limit confidence in broad ONS adoption.

As a result, ONS for these indications is generally considered experimental or not medically necessary outside of research or specialized tertiary care review.

Noninvasive neuromodulation methods summarized in the policy include vagus nerve stimulation (nVNS), external trigeminal/supraorbital stimulation (eTNS/SON), repetitive TMS (rTMS), and transcranial direct current stimulation (tDCS). Guideline bodies (VA/DoD, NICE) report insufficient or limited evidence for routine use of many of these technologies and recommend special governance, consent, and research contexts for some indications (e.g., transcutaneous SON stimulation for acute migraine per NICE).

The policy therefore treats these noninvasive neuromodulation options as having variable, generally low‑quality evidence and appropriate mainly within defined research or special‑arrangement settings.

The document’s coding section references spine/rhizotomy and related CPT codes as anchors to the coding tables; examples include 63185 and 63190 for laminectomy with rhizotomy. These coding entries are intended as a cross‑link to the CODING section where full procedure and diagnosis code groups are listed.

Inclusion of these codes is for reference only and does not by itself imply coverage — benefit determination remains subject to applicable plan terms and medical necessity criteria.

Required conservative therapy and stepwise approach

Conservative treatment requirements

Conservative-first approach and documentation expectations

Top-level conservative requirement: Document prior conservative therapies attempted (e.g., medications, physical therapy) and inadequate response before considering long-term, repeat, or more invasive interventions such as neurostimulation, PRF, RFA, or surgery.

Policy and evidence reviews consistently select or recommend patients who failed conservative care before advanced interventions

Document prior conservative therapies attempted and inadequate response before long-term or repeat interventions

Documentation of prior therapies: Provider documentation must describe prior standard medical therapies attempted and inadequate response (for example failed preventive medications, abortive agents, or a course of physical therapy) when requesting long-term or repeat occipital nerve interventions.

Prior authorization, documentation, and operational guidance

Prior Authorization

Prior authorization advisable for repeat blocks and surgery

Prior authorization is generally advisable for repeat greater occipital nerve blocks and for surgical procedures for occipital neuralgia or cervicogenic headache. Repeated interventional procedures and invasive surgeries may be subject to utilization review given limited and variable evidence of long‑term benefit.

Prior authorization advisable for repeat blocks and surgery

Prior Authorization

Prior authorization for RFA and neurodestructive procedures

Prior authorization is expected for radiofrequency ablation (thermal or pulsed) and other neuro‑destructive procedures. Documentation should demonstrate prior conservative therapy failure and justification for a neurodestructive approach given mixed evidence and potential for complications.

Prior authorization for RFA and neurodestructive procedures

Prior Authorization

Procedure, diagnosis, and device codes

Referenced spine/rhizotomy CPT codesCPT

63185	Laminectomy with rhizotomy; 1 or 2 segments.
63190	Laminectomy with rhizotomy; more than 2 segments

Referenced neurostimulation, injection, and neurolytic CPT codesCPT

64405	Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve.
64553	Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64568	Open implantation of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64570	Removal of cranial nerve (e.g., vagus nerve) neurostimulator electrode array and pulse generator.
64575	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure).
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.

1–10 of 13

1/2

Referenced surgical and HCPCS codesmixed

64744	Transection or avulsion of; greater occipital nerve.
64771	Transection or avulsion of other cranial nerve, extradural.
64999	Unlisted procedure, nervous system.
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm.
L8679	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.

Referenced diagnosis codesICD-10

C76.0
G89.3	Neoplasm related pain (acute) (chronic).

Example procedural codes discussed in context of RFA/neurodestructionCPT

64640	Destruction by neurolytic agent; other peripheral nerve
64635	Destruction of other peripheral nerve(s) by neurolytic agent
61299	Unlisted cranial procedure (placeholder example from policy context)

Procedures discussed (no explicit billing codes in excerpt)mixed

No codes listed

RFA device product codesmixed

GXD	FDA product code for radiofrequency lesion generators
GXI	FDA product code for radiofrequency lesion probes

Electrical stimulation device product codes / clearancesmixed

GZF	FDA product code for certain electrical stimulation devices
GZB	FDA product code for certain electrical stimulation devices
PCC	FDA product code for certain electrical stimulation devices
K203181	FDA De Novo / 510(k) identifier for Nerivio Migra

MIDAS score — interpretation

MIDAS cutoffMIDAS score ≥ 6 prompts discussion with a provider (indicates at least mild disability)

MIDAS purposeQuestionnaire measuring headache-related disability; total from Q1–Q5 used to classify I (0–5) to IV (21+)

MIDAS categoriesI: 0–5 (little/no disability); II: 6–10 (mild); III: 11–20 (moderate); IV: 21+ (severe)

Temporary trial — response threshold

Temporary trial response thresholdA response of ≥ 50% reduction in pain/headache frequency is commonly used to select candidates for permanent occipital nerve stimulation (ONS)

Frequency limits and imaging guidance

GONB — trial descriptions and frequency note

GONB in trialsTrials describe repeated GONB courses (e.g., four-weekly injections over 12 weeks) used for prevention/treatment

No explicit payer frequency limit in policy segmentPolicy notes GONB described with repeated injections but does not state an explicit payer frequency limit in this section

Typical injectate and schedule examplesExamples include 2 mL bilateral 2% lidocaine given four-weekly for 12 weeks or weekly x3 series then monthly as clinically indicated

GONB study frequencies — short series and outcomes

Short-series regimens reportedStudies report short series such as once-weekly injections for 3–4 weeks (e.g., weekly x3 to weekly x4) with short-term benefit

Observed benefit duration

Clinical background and definitions

The policy background summarizes cervicogenic headache and occipital neuralgia as conditions believed to arise from impingement, entrapment, or pathology of the occipital nerves and upper cervical roots (C1–C3). Typical clinical features include unilateral or bilateral head and neck pain with occipital distribution, and symptoms can overlap with migraine and other primary headache disorders.

Management options span conservative medical therapies, diagnostic and therapeutic occipital nerve blocks (GONB/LON), image‑guided interventions, neurolytic ablation for malignant pain, radiofrequency techniques, surgical decompression or neurectomy, and neurostimulation approaches — each with variable evidence supporting specific uses.

Cervicogenic Headache — definition

DefinitionCervicogenic Headache: Referred pain perceived in the head from a source in the neck due to disorders of the cervical spine and its components.

SourceDefinition per policy (American Migraine Foundation reference) included in policy definitions section.

Clinical implicationConsider cervical spine pathology evaluation when cervicogenic headache suspected; diagnosis guides selection of interventions such as nerve blocks or RFA.

Procedures considered not medically necessary or investigational

Under the policy’s NOT COVERED section, neurostimulation/electrical stimulation for occipital neuralgia or headache indications is listed as unproven and not medically necessary in many contexts due to limited, low‑quality evidence and methodological flaws in available studies.

Specific examples include implantable occipital nerve stimulation for chronic cluster headache and other off‑label headache indications, where guideline and technology assessments found insufficient robust RCT evidence to support routine coverage; such requests may therefore be denied unless they meet narrowly defined, evidence‑supported criteria.

Policy revision history and material changes

2025-10-01policy_revisionLatest

Added coverage language: occipital nerve ablation (destruction by neurolytic agent) is proven and medically necessary for treating pain due to malignancy involving the head and neck; removed instruction to refer to InterQual® CP: Procedures, Neuroablation, Percutaneous for these criteria; added definitions for the Migraine Disability Assessment Test (MIDAS) and Migraine‑Specific Quality of Life Questionnaire (MSQ).

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) (for Kansas Only)

Policy CodePolicy CS086KS.02

Change TypeMaterial coverage updatedefinitions added

Effective DateOct 1, 2025

Next Review Date

Key ActionDocument prior conservative therapy failure and diagnostic block response when requesting authorization; note occipital nerve ablation is proven for malignancy-related head/neck pain.

SourceLink

On This Page

Surgical interventions and neuroplasty evidence: Surgical procedures (neurectomy, decompression, neuroplasty, migraine surgery) and some RFA approaches have insufficient high-quality RCT evidence to establish long-term effectiveness despite some case series and uncontrolled reports showing benefit for selected patients.

Systematic reviews (McNutt et al., Hayes briefs) report no RCTs or low-quality evidence for many surgical techniques

Hayes HTA and trial reports note selection of patients with inadequate response to standard care

Conservative-first approach with documented failure before progressing to RFA or surgery

Conservative-first before RFA/surgery: Before performing RFA, neurodestructive or surgical procedures, document trial and failure of conservative medical management (medications, physical therapy) and consideration or trial of diagnostic/therapeutic occipital nerve blocks.

RCTs and systematic reviews generally enroll patients after conservative therapy failure and recommend diagnostic blocks prior to RFN

Documented failure of appropriate conservative therapies prior to considering neurostimulation/PRF

Prior failure required for neurostimulation/PRF: Documented inadequate response to appropriate conservative therapies (pharmacologic and nonpharmacologic) is expected before considering occipital nerve stimulation or pulsed radiofrequency; many studies required prior failure and trial-based selection for enrollment.

Hayes HTA and PRF/RFA studies typically selected patients after failed conservative care

Documented inadequate response or intolerance to medical therapy required prior to advanced interventions

Documented inadequate response or intolerance to medical therapy

Medication trial requirement: Prior inadequate response or intolerance to standard migraine-specific medications (acute and preventive agents) should be documented before considering invasive neuromodulation; guideline panels emphasize exhausting standard medical therapies first.

NICE and AHS guidance recommend use of standard medical therapies prior to invasive procedures

Trial of standard medical therapies and specialist selection prior to invasive neuromodulation

Standard therapy and specialist selection: Document trial of standard acute and preventive therapies per guideline recommendations and ensure patient selection and management involve clinicians with headache expertise prior to invasive neuromodulation or device implantation.

NICE and VA/DoD guidance emphasize using established medical therapies and specialist assessment before invasive options

Prior authorization and trial requirement

Prior authorization and, when applicable, documentation of a successful temporary trial are typically required before proceeding to permanent neurostimulation (e.g., occipital nerve stimulation). Specify trial parameters and outcomes in the request.

Prior authorization and trial requirement (temporary trial response commonly ≥50%)

Prior Authorization

Prior authorization expected for invasive neurostimulation

Invasive neurostimulation procedures (implantation of leads, pulse generators) are expected to require prior authorization due to heterogeneous evidence, device‑related risks, and potential need for revision surgery. Provide prior conservative management, specialist evaluation, and trial results.

Prior authorization expected for invasive neurostimulation

Denial Risk

Denial risk for unproven procedures

Some procedures are considered unproven or not medically necessary and have a high risk of denial. These include occipital neurectomy, certain non‑pulsed RFA techniques, and some neurostimulation indications where evidence is insufficient.

Denial risk for unproven procedures (neurectomy, nonpulsed RFA, select neurostimulation uses)

Denial Risk

Evidence limitations may trigger coverage scrutiny

Limitations in the evidence base (small sample sizes, heterogeneity of methods, short follow‑up, low quality ratings) may trigger closer coverage scrutiny and requests for additional documentation to support medical necessity.

Evidence limitations may trigger coverage scrutiny

Denial Risk

Evidence insufficiency may trigger denial

Where evidence is insufficient or of very low quality for a specific indication (for example, ONS for some cluster headache indications or surgical decompression/neurectomy), requests may be denied unless strong, case‑specific justification and outcome data are provided.

Evidence insufficiency may trigger denial

Documentation Required

Special arrangements required per NICE

Certain procedures involving transcutaneous electrical stimulation or other novel device‑based therapies may require special arrangements as recommended by NICE — including clinical governance, informed consent documentation, and local audit or research participation.

Special arrangements required per NICE (clinical governance, consent, audit/research)

Documentation Required

Coverage governance and denial risk

Coverage determinations must follow applicable federal, state, and contractual plan terms; in the event of conflict, those terms govern. Prior authorization and denial decisions should be consistent with plan contract language and applicable regulatory requirements.

Coverage governance and denial risk — follow federal/state/contractual plan terms

Documentation Required

Suggested documentation elements from RCTs

When submitting requests, include key elements drawn from randomized controlled trials and other studies: baseline pain/frequency scores, duration of prior therapies, objective outcome measures (e.g., VAS, MIDAS, headache days/month), short‑term response and reported adverse events.

Suggested documentation elements from RCTs: baseline pain scores, MIDAS/MSQ where applicable, follow‑up time points, adverse events

Documentation Required

Required clinical documentation

Required clinical documentation for prior authorization requests should include: a clear diagnosis with supporting clinical criteria (IHS/ICHD where relevant), documentation of failure or intolerance of conservative therapies, prior response to diagnostic blocks (if applicable), and evaluation by an appropriate specialist (neurology or pain specialist).

Required clinical documentation: diagnosis, conservative therapy failure, diagnostic block response, specialist evaluation

Documentation Required

Suggested documentation for neurostimulation requests

For neurostimulation requests, provide: indication and rationale, documentation of conservative therapy attempts, results of temporary stimulation trial (report magnitude and duration of response; commonly ≥50% improvement), device model and proposed implant procedure, and plan for follow‑up.

Suggested documentation for neurostimulation requests: trial response, device info, follow‑up plan

Documentation Required

Trial response and prior therapy documentation

Document clearly the temporary trial response (thresholds commonly reported as ≥50% pain reduction), duration of benefit from the trial, prior therapies attempted and their durations, and any adverse events experienced during trials or prior procedures.

Trial response and prior therapy documentation (temporary trial response commonly ≥50%)

Documentation Required

Documentation and governance

Maintain records of informed consent, discussion of risks/benefits, and local clinical governance processes for high‑risk or novel procedures. For interventions recommended by NICE with 'special arrangements', ensure participation in audit or outcome reporting when requested.

Documentation and governance: informed consent, outcome audit, clinical governance

Note

Use InterQual for cancer-related neuroablation

UnitedHealthcare uses InterQual® for certain neuroablation indications. For severe cancer‑related occipital nerve ablation (head and neck malignancy), refer to InterQual® CP: Procedures, Neuroablation, Percutaneous when applicable and include InterQual® criteria citations in the authorization request.

Use InterQual for cancer‑related neuroablation where applicable

Step Therapy

Stepwise approach supported by evidence reviews

The evidence supports a stepwise approach: begin with conservative therapies (pharmacologic management, physical therapy, noninvasive neuromodulation where appropriate), progress to diagnostic nerve blocks to identify responders, and consider escalation to RFA, neurodestructive procedures, or neurostimulation only after demonstrated failure of conservative measures and appropriate diagnostic confirmation.

Stepwise approach supported by evidence reviews — conservative → diagnostic blocks → escalation

Step Therapy

Conservative therapy precedence

Guidelines and reviews emphasize that standard medical therapies (pharmacologic prevention and acute treatments, physical therapy, behavioral therapies) should usually be tried before invasive procedures. Document adequacy and duration of prior conservative therapy trials in authorization requests.

Conservative therapy precedence — document trials of medical therapy before invasive options

Trial duration contextTrials typically last a few weeks; documented sustained ≥50% improvement during the trial period is used for selection

Supporting evidenceHayes assessment and RCTs/series report trial-based selection with ≥50% threshold for permanent implantation

Benefits are primarily short-term (improvements at 1–2 months reported in systematic reviews and RCTs)

Clinical follow-up practiceSome cohorts extend to monthly injections for up to six months based on clinical response in observational studies

RFA / pulsed RFA — frequency notes

RFA / pulsed RFA frequency — summaryPolicy describes RFA and pulsed RFA studies but does not define explicit repeat-frequency limits in this segment

Evidence on duration of benefitRFA studies report mean duration of improvement (e.g., retrospective series reporting average ~254 days) and variable follow-up intervals

Recommendation contextASPN notes diagnostic blockade should precede RFN; time/lesion settings vary and further study needed to define repeat-session guidance

Pulsed RF (PRF/PRFN) — frequency notes

PRF frequency — summaryPulsed RF (PRF/PRFN) studies report variable treatment schedules and follow-up; policy does not specify a standardized repeat frequency here

Duration of effect reportedPRF/PRFN cohorts report significant analgesia from 3–10 months in some series depending on target and indication

Imaging and technique variabilityPRF studies use CT or ultrasound guidance variably; optimal target and settings remain unclear

Occipital RFN — repeat session and duration notes

RFN repeat sessionsRepeat occipital radiofrequency neurotomy (RFN) sessions are not well-defined in the literature; several studies documented up to six months of pain relief

Pre-procedure imaging recommendationASPN recommends ruling out other etiologies with MRI and/or CT prior to RFN; imaging does not diagnose ON but is used to exclude other causes

Technique/time settingsASPN notes lesion time settings vary (single lesion ~90 seconds to up to three lesions of 120 seconds); further studies needed to guide repeat-session recommendations

Frequency — not specified / placeholder

Frequency not specifiedThis section does not specify a frequency limit for certain procedures; absent explicit policy frequency, clinical trial protocols and literature guides practice

Use evidence to inform repeatsWhere frequency is unspecified, documented clinical benefit and peer-reviewed study protocols are referenced to justify repeat treatments

Prior authorization implicationPrior authorization may be required for repeat or surgical procedures pending evidence of prior conservative therapies and documented benefit

Billing Rule

Follow CPT-referenced imaging guidance for neurolytic, stimulator, and RFA procedures

Imaging guidance is referenced in CPT descriptors for neurolytic destruction, neurostimulator procedures, and radiofrequency ablation; perform and document image guidance as appropriate per CPT and procedural standards.

CPT descriptors note fluoroscopy or CT guidance for neurolytic destruction and imaging guidance clauses for implant procedures.

Billing Rule

Document image guidance for GONB (ultrasound commonly used)

Ultrasound or other image guidance is commonly used for greater occipital nerve blocks (GONB); document the use of image guidance in the procedure note.

Trials and RCTs report US-guided GONB techniques; include imaging modality in documentation.

Billing Rule

Use and document appropriate image guidance for nerve blocks, PRF, and RFA

Use appropriate imaging guidance (ultrasound, CT, or fluoroscopy) for nerve blocks, pulsed RF, and thermal RFA as indicated by the target and procedural standards; record modality used.

Studies utilized US, CT, or fluoroscopy depending on the procedure and target (e.g., SPG, GON, C2 DRG).

Billing Rule

Document imaging method for PRF to SPG or GON (CT or US reported)

Imaging guidance for pulsed RF to the sphenopalatine ganglion (SPG) or GON varies by study (CT or ultrasound reported); document the guidance method used for the procedure.

PRF studies report CT-guided or US-guided approaches for SPG and GON targets.

Billing Rule

Obtain MRI and/or CT prior to occipital RFN to exclude other causes

Prior to occipital radiofrequency neurotomy (RFN), rule out other etiologies with MRI and/or CT as recommended; imaging is not diagnostic for occipital neuralgia but aids evaluation.

ASPN best-practice guidance recommends MRI and/or CT before RFN to exclude other causes.

Billing Rule

Follow guideline-recommended conditional imaging for cluster headache evaluation

For cluster headache evaluation, neuroimaging is conditionally recommended (discussing first bout with a GP with special interest or neurologist); follow guideline recommendations and document imaging decisions.

NICE recommends discussing need for neuroimaging for a first bout of cluster headache with a clinician experienced in headache.

MIDAS — definition and categories

MIDAS purpose and scoringMIDAS measures headache-related disability; scores: I (0–5), II (6–10), III (11–20), IV (21+)

Actionable thresholdMIDAS score ≥ 6 indicates discussion with a provider is recommended

Use in policyMIDAS added to policy definitions to aid assessment of headache-related disability and treatment decisions

MSQ — definition

MSQ descriptionMigraine-Specific Quality of Life Questionnaire (MSQ): 14-item self-report assessing role, emotional, and social functioning impact of migraine.

Scoring formatItems rated on a 6-point Likert scale (1 = very poor to 6 = very good); used to capture quality-of-life change in trials up to 52 weeks.

Policy inclusionMSQ added to policy definitions to standardize outcome reporting for neuromodulation and other interventions.

Migraine Headache Index (MHI) — definition

MHI definitionMigraine Headache Index (MHI): composite metric multiplying migraine severity, frequency, and duration used in surgical outcome analyses.

Use caseUsed to compare pre- and postoperative headache burden in migraine surgery studies (reported reductions in pooled analyses).

InterpretationChange in MHI over follow-up used as an outcome measure for effectiveness of surgical interventions.

Greater occipital nerve block (GONB) — definition and use

GONB definitionGreater occipital nerve block (GONB): injection of local anesthetic, sometimes with corticosteroid, in the occipital region targeting the GON for diagnostic or therapeutic purposes.

Clinical usesUsed diagnostically to identify occipital nerve–mediated pain and therapeutically to provide short-term reduction in headache intensity/frequency.

Evidence summaryRCTs and systematic reviews show short-term benefit (up to 1–2 months) though evidence quality is limited and chronic preventive effect is uncertain.

Occipital nerve block (GONB/LON) — definition

Occipital nerve block (GONB/LON)Diagnostic and therapeutic injection of local anesthetic (often with steroid) targeting greater or lesser occipital nerves to identify nerve-mediated pain and provide transient relief.

Typical protocolsProtocols vary from single injection to short series (weekly x3–4) or four-weekly injections over several weeks as used in trials.

Predictive valuePositive short-term response to diagnostic block is used in selection for more definitive procedures (e.g., RFA or neurostimulation)

Pulsed radiofrequency (PRF) — definition

Pulsed radiofrequency (PRF) — basic definitionPulsed radiofrequency (PRF): a non‑ablative RF technique delivering intermittent high‑voltage pulses intended to modulate pain signaling with lower risk of neurodestruction compared to continuous thermal RFA.

Clinical intentUsed to reduce pain while avoiding thermal lesioning; effectiveness measured by reductions in pain scores and headache frequency over months in some series.

Evidence limitationsStudies are heterogeneous with variable targets, settings, and follow-up; optimal parameters and repeat-frequency remain unclear.

Pulsed radiofrequency (PRF/PRFN) — definition

PRF/PRFN — neuromodulation definitionPulsed radiofrequency neuromodulation (PRFN): delivery of pulsed energy to peripheral nerves or ganglia (e.g., GON, SPG) to reduce pain without thermal ablation.

Reported outcomesReviews report analgesic benefit from 3–10 months for chronic migraine and occipital neuralgia in low‑quality evidence bodies.

Technique variabilityImage guidance (CT or US) and procedural parameters vary across studies; standardized protocols are lacking.

Occipital nerve stimulation (ONS) — definition and practice

ONS definitionOccipital nerve stimulation (ONS): implantation of leads to stimulate occipital nerves for chronic headache or occipital neuralgia, typically preceded by a temporary trial.

Trial and implant practicePermanent implantation is commonly preceded by a temporary trial; selection often requires a ≥50% reduction in pain during the trial.

Outcomes and risksReported responder rates and long‑term responder ranges vary widely; device complications (lead migration, infection) are notable considerations.

Temporary trial of ONS — definition and threshold

Temporary trial of ONS — definitionA short‑duration test stimulation prior to permanent implantation, commonly using a response threshold of ≥50% reduction in pain lasting for the trial duration to select candidates.

Typical trial length and outcomesTrials usually last a few weeks; outcomes assessed include reduction in headache frequency/intensity and patient‑reported improvements.

Documentation importanceProviders should document trial response (≥50% improvement) and prior conservative therapy failures when seeking authorization for permanent ONS.

Diagnostic occipital nerve block — definition and predictive use

Diagnostic occipital nerve block — definitionA local anesthetic injection to identify occipital nerves as the pain etiology and to predict response to occipital RFN or neurostimulation.

Predictive roleA definite positive response (e.g., ≥50% pain relief) to a diagnostic block is associated with better outcomes after subsequent procedures.

Use in selection criteriaPolicy guidance uses diagnostic block response as a key selection factor for RFA/pulsed RFA and neurostimulation candidacy.

Radiofrequency ablation (RFA) — definition

RFA — procedure definitionRadiofrequency ablation (RFA): percutaneous procedure using lesion generators and probes (FDA product codes GXD, GXI) to create thermal lesions for denervation.

Device regulation noteDevices used for RFA are FDA‑regulated (product codes cited) though the procedure itself is not regulated by FDA approval.

Clinical evidenceSystematic reviews report favorable outcomes but heterogeneity and lack of standardized protocols limit definitive recommendations.

Transcutaneous electrical stimulation (eTNS) — definition

eTNS definitionTranscutaneous electrical stimulation of the supraorbital nerve (eTNS / SON): noninvasive forehead‑applied device delivering small electrical currents to branches of the ophthalmic nerve for acute and preventive migraine treatment.

Usage and regimenDevices are self‑administered; stimulation may be applied daily for 1–2 hours for acute attacks or ~20 minutes for prevention depending on guidance.

NICE recommendationNICE recommends special arrangements (governance, consent, audit/research) for use in some contexts, especially prevention.

MIDAS — policy definition addition

MIDAS addedMIDAS (Migraine Disability Assessment Test) was added to the policy definitions in the 10/01/2025 revision.

ReasonIncluded to standardize assessment of headache‑related disability and guide treatment discussions.

ReferencePolicy History/Revision Information documents the addition as a material change.

MSQ — policy definition addition

MSQ addedMSQ (Migraine‑Specific Quality of Life Questionnaire) was added to the policy definitions in the 10/01/2025 revision.

PurposeAdded to standardize quality‑of‑life outcome measures referenced in device and procedural studies.

Policy change noteDocumented in Policy History/Revision Information as an added definition.